Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy

SIMPLE SUMMARY: More than half of children with high-risk neuroblastoma will not survive despite aggressive treatment regimens. The discovery of suitable novel therapies that target high-risk disease remain limited. Oncolytic virotherapy employs common viruses, such as herpes simplex virus. These vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Quinn, Colin H., Beierle, Andee M., Hutchins, Sara Claire, Marayati, Raoud, Bownes, Laura V., Stewart, Jerry E., Markert, Hooper R., Erwin, Michael H., Aye, Jamie M., Yoon, Karina J., Friedman, Gregory K., Willey, Christopher D., Markert, James M., Beierle, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834037/
https://www.ncbi.nlm.nih.gov/pubmed/35159029
http://dx.doi.org/10.3390/cancers14030762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834037/
https://www.ncbi.nlm.nih.gov/pubmed/35159029
http://dx.doi.org/10.3390/cancers14030762

Ejemplares similares